A waiver on some intellectual property rules at the WTO for COVID-19 vaccines would ensure more equitable access, but wouldn't solve all the problems facing developing countries.
Academic rigor, journalistic flair
Articles on TRIPS
Displaying all articles
The TRIPS waiver makes COVID-19 treatments more accessible globally by enabling manufacture and distribution of COVID-19 drugs and medical supplies that would normally be protected by patents.
There's a risk Australia won't get access to everything it will need need. It can take are simple stepsto make sure patents don't get in the way.
After nearly two decades of legal battles and negotiations, South Africa is moving to cut the cost of medicines with policies to increase imports and local production of generic drugs.
There is a window of opportunity for the least developed countries to develop their own pharmaceuticals industry.
Seven rounds of negotiations for the Regional Comprehensive Economic Partnership have already taken place with virtually no public debate. The next round of negotiations begins today in Kyoto, Japan.
India is the global focal point for legal and political struggles over patent rights and access to medicines. Particular attention is focused on the Swiss pharmaceutical giant Novartis, which is in battle…
Two large multinational pharmaceutical companies are fighting for patents and monopoly pricing in Indian courts. The outcomes of the cases – involving Novartis and Bayer – are likely to determine the country’s…
The Anti-Counterfeiting Trade Agreement (ACTA) 2011 - Twitter hashtag #ACTA - is a controversial trade agreement designed to provide for stronger enforcement of intellectual property rights. There’s been…
Top contributors
-
Senior Lecturer in Public Health, La Trobe University
-
Associate Professor Politics and Policy Studies, Deakin University
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Scholar Emeritus in the School of Public Health & Human Biosciences, La Trobe University
-
Professor in Intellectual Property and Innovation Law, Queensland University of Technology
-
Reader in Intellectual Property Law, City, University of London
-
Research Fellow, NHMRC Centre for Research Excellence in the Social Determinants of Health Equity, School of Regulation and Global Governance, Australian National University
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Associate Professor and Course Leader: Post Graduate Programmes in Clinical Pharmacy in the Department of Pharmacy, Sefako Makgatho Health Sciences University
-
Professeure titulaire, École de santé publique, Université de Montréal
-
Professor of Law, Northeastern University
